华润三九 reported revenue of ¥15.01B for the period ended 2026-06-30, +1.4% year on year. Net income was ¥2.00B, a 13.3% net margin on a 56.8% gross margin. The largest revenue line is 医药行业-处方药 at 46% of the total. Free cash flow for the period was ¥1.08B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥15.01B | +1.4% |
| Gross profit | ¥8.53B | — |
| Operating income | ¥2.50B | — |
| Net income | ¥2.00B | -9.5% |
| Gross margin | 56.8% | Net margin 13.3% |
| Revenue Q/Q | -15.3% | — |
| Segment | Revenue | Share |
|---|---|---|
| 医药行业-处方药 | ¥6.88B | 45.8% |
| 医药行业-自我诊疗(CHC) | ¥6.13B | 40.8% |
| 药品、器械批发及零售 | ¥1.73B | 11.5% |
| 包装印刷 | ¥0.27B | 1.8% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥6.49B | 43.2% |
| R&D | ¥0.60B | 4.0% |
| SG&A | ¥5.09B | 33.9% |
| Tax & other | ¥0.50B | 3.3% |
| Item | Amount |
|---|---|
| Total assets | ¥55.84B |
| Total liabilities | ¥16.71B |
| Shareholders' equity | ¥39.13B |
| Equity / assets | 70.1% |
| Operating cash flow | ¥1.37B |
| Capital expenditure | ¥0.28B |
| Free cash flow | ¥1.08B |
| Cash conversion (OCF / net income) | 121% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
中国铀业 ・ 国货航 ・ 招商公路 ・ 招商蛇口 ・ 新和成 ・ 分众传媒 ・ 思源电气 ・ 紫光国微 ・ 三花智控 ・ 国轩高科 ・ 宁波银行 ・ 中航光电
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies